Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Bouffard, Amanda A."" wg kryterium: Autor


Wyświetlanie 1-20 z 20
Tytuł :
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Autorzy :
Choi, Bryan D.Aff1, Aff2
Yu, Xiaoling
Castano, Ana P.
Bouffard, Amanda A.
Schmidts, Andrea
Larson, Rebecca C.
Bailey, Stefanie R.
Boroughs, Angela C.
Frigault, Matthew J.Aff1, Aff3
Leick, Mark B.
Scarfò, Irene
Cetrulo, Curtis L.
Demehri, Shadmehr
Nahed, Brian V.
Cahill, Daniel P.
Wakimoto, Hiroaki
Curry, William T.
Carter, Bob S.
Maus, Marcela V.Aff1, Aff3
Pokaż więcej
Źródło :
Nature Biotechnology: The Science and Business of Biotechnology. 37(9):1049-1058
Czasopismo naukowe
Tytuł :
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
Autorzy :
Choi, Bryan D.Aff1, Aff2
Yu, Xiaoling
Castano, Ana P.
Darr, Henia
Henderson, Daniel B.
Bouffard, Amanda A.
Larson, Rebecca C.
Scarfò, Irene
Bailey, Stefanie R.
Gerhard, Genevieve M.
Frigault, Matthew J.Aff1, Aff4
Leick, Mark B.
Schmidts, Andrea
Sagert, Jason G.
Curry, William T.
Carter, Bob S.
Maus, Marcela V.Aff1, Aff4
Pokaż więcej
Źródło :
Journal for ImmunoTherapy of Cancer. 7(1)
Czasopismo naukowe
Tytuł :
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Autorzy :
Schmidts, Andrea
Ormhøj, Maria
Choi, Bryan D.
Taylor, Allison O.
Bouffard, Amanda A.
Scarfò, Irene
Larson, Rebecca C.
Frigault, Matthew J.
Gallagher, Kathleen
Castano, Ana P.
Riley, Lauren S.
Cabral, Maria L.
Boroughs, Angela C.
Velasco Cárdenas, Rubí M.H.
Schamel, Wolfgang
Zhou, Jing
Mackay, Sean
Tai, Yu Tzu
Anderson, Kenneth C.
Maus, Marcela V.
Pokaż więcej
Temat :
Immunobiology and Immunotherapy
Źródło :
Schmidts, A, Ormhøj, M, Choi, B D, Taylor, A O, Bouffard, A A, Scarfò, I, Larson, R C, Frigault, M J, Gallagher, K, Castano, A P, Riley, L S, Cabral, M L, Boroughs, A C, Velasco Cárdenas, R M H, Schamel, W, Zhou, J, Mackay, S, Tai, Y T, Anderson, K C & Maus, M V 2019, ' Rational design of a trimeric April-based CAR-binding domain enables efficient targeting of multiple myeloma ', Blood Advances, vol. 3, no. 21, pp. 3248-3260 . https://doi.org/10.1182/bloodadvances.2019000703
Opis pliku :
application/pdf
Tytuł :
Targeting CD79b with chimeric antigen receptors shows potent pre-clinical efficacy in mantle cell lymphoma
Autorzy :
Ormhøj, Maria
Scarfò, Irene
Andersen, Rikke Sick
Cédile, Oriane
Bailey, Stefanie R
Lorrey, Selena
Bouffard, Amanda A.
Castano, Ana P.
Nyvold, Charlotte Guldborg
Christensen, Jacob Haaber
Gjerstorff, Morten
Ditzel, Henrik
Weinstock, David M.
Barington, Torben
Maus, Marcela V.
Pokaż więcej
Źródło :
Ormhøj, M, Scarfò, I, Andersen, R S, Cédile, O, Bailey, S R, Lorrey, S, Bouffard, A A, Castano, A P, Nyvold, C G, Christensen, J H, Gjerstorff, M, Ditzel, H, Weinstock, D M, Barington, T & Maus, M V 2019, ' Targeting CD79b with chimeric antigen receptors shows potent pre-clinical efficacy in mantle cell lymphoma ', 1st European CAR T Cell Meeting, Paris, Paris, France, 14/02/2019 - 16/02/2019 .
Tytuł :
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Autorzy :
Ormhøj M; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.; Department of Clinical Immunology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
Scarfò I; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Cabral ML; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Bailey SR; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Lorrey SJ; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Bouffard AA; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Castano AP; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Larson RC; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Riley LS; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Schmidts A; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Choi BD; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Andersen RS; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Cédile O; Haematology-Pathology Research Laboratory, Odense University Hospital, University of Southern Denmark, Odense, Denmark.; Department of Pathology, Odense University Hospital, Odense, Denmark.; OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.
Nyvold CG; Haematology-Pathology Research Laboratory, Odense University Hospital, University of Southern Denmark, Odense, Denmark.; Department of Pathology, Odense University Hospital, Odense, Denmark.; OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.
Christensen JH; Department of Haematology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
Gjerstorff MF; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.; Department of Oncology, Odense University Hospital, Odense, Denmark.
Ditzel HJ; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.; Department of Oncology, Odense University Hospital, Odense, Denmark.
Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Barington T; Department of Clinical Immunology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.; OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.
Frigault MJ; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Maus MV; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. .; Harvard Medical School, Boston, Massachusetts.
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Dec 01; Vol. 25 (23), pp. 7046-7057. Date of Electronic Publication: 2019 Aug 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD19/*immunology
CD79 Antigens/*immunology
Immunotherapy, Adoptive/*methods
Lymphoma, Mantle-Cell/*therapy
Receptors, Chimeric Antigen/*immunology
T-Lymphocytes/*immunology
Animals ; Apoptosis ; Cell Proliferation ; Humans ; Lymphocyte Activation ; Lymphoma, Mantle-Cell/immunology ; Lymphoma, Mantle-Cell/metabolism ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Prognosis ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
Autorzy :
Schmidts A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Ormhøj M; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Clinical Immunology, University of Southern Denmark, Odense, Denmark.
Choi BD; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Neurosurgery and.
Taylor AO; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.
Bouffard AA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.
Scarfò I; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Larson RC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Frigault MJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Gallagher K; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA.
Castano AP; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.
Riley LS; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.
Cabral ML; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.
Boroughs AC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Velasco Cárdenas RM; Department of Immunology, Faculty of Biology.; Center for Biological Signaling Studies (BIOSS), and.; Center for Integrative Biological Signaling Studies (CIBSS), University of Freiburg, Freiburg, Germany.
Schamel W; Department of Immunology, Faculty of Biology.; Center for Biological Signaling Studies (BIOSS), and.; Center for Integrative Biological Signaling Studies (CIBSS), University of Freiburg, Freiburg, Germany.
Zhou J; Isoplexis, Branford, CT; and.
Mackay S; Isoplexis, Branford, CT; and.
Tai YT; Department of Medicine, Harvard Medical School, Boston, MA.; LeBow Institute for Myeloma Therapeutics and.; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.
Anderson KC; Department of Medicine, Harvard Medical School, Boston, MA.; LeBow Institute for Myeloma Therapeutics and.; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.
Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2019 Nov 12; Vol. 3 (21), pp. 3248-3260.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, Neoplasm*/immunology
Immunotherapy, Adoptive*/adverse effects
Immunotherapy, Adoptive*/methods
Multiple Myeloma/*immunology
Multiple Myeloma/*therapy
Receptors, Chimeric Antigen/*metabolism
T-Lymphocytes/*immunology
T-Lymphocytes/*metabolism
Tumor Necrosis Factor Ligand Superfamily Member 13/*antagonists & inhibitors
Animals ; Cytokines/metabolism ; Cytotoxicity, Immunologic ; Disease Models, Animal ; Humans ; Lymphocyte Activation/immunology ; Mice ; Protein Binding/immunology ; Receptors, Chimeric Antigen/genetics ; T-Cell Antigen Receptor Specificity ; Tumor Necrosis Factor Ligand Superfamily Member 13/immunology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
    Wyświetlanie 1-20 z 20

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies